Zyversa Therapeutics Inc ZVSA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 02/04/23 EST
2.32quote price arrow down-0.11 (-4.53%)
Volume
12,350
Close
2.43quote price arrow up+0.09 (+3.85%)
Volume
361,119
52 week range
1.38 - 25.00
Loading...
  • Open2.23
  • Day High2.70
  • Day Low2.22
  • Prev Close2.34
  • 52 Week High25.00
  • 52 Week High Date12/12/22
  • 52 Week Low1.38
  • 52 Week Low Date12/30/22

Key Stats

  • Market Cap22.069M
  • Shares Out9.08M
  • 10 Day Average Volume0.59M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change54.78

KEY STATS

  • Open2.23
  • Day High2.70
  • Day Low2.22
  • Prev Close2.34
  • 52 Week High25.00
  • 52 Week High Date12/12/22
  • 52 Week Low1.38
  • 52 Week Low Date12/30/22
  • Market Cap22.069M
  • Shares Out9.08M
  • 10 Day Average Volume0.59M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change54.78

RATIOS/PROFITABILITY

  • EPS (TTM)-0.20
  • P/E (TTM)-11.94
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-2.519M
  • ROE (TTM)-5.46%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Zyversa Therapeutics Inc

 

Profile

MORE
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on leveraging advanced technologies to develop drugs for patients with renal or inflammatory diseases. The Company’s development pipeline includes renal drug candidate, namely VAR 200, (2-hydroxypropyl-beta-cyclodextrin or 2HPβCD), a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. Its VAR 200 has potential to treat...
Stephen Glover
Chairman of the Board, Chief Executive Officer
Peter Wolfe
Chief Financial Officer
Address
2200 N. Commerce Parkway, Suite 208
Weston, FL
33326
United States